WO2017139664A8 - Intermediates in the synthesis of eribulin and related methods of synthesis - Google Patents

Intermediates in the synthesis of eribulin and related methods of synthesis Download PDF

Info

Publication number
WO2017139664A8
WO2017139664A8 PCT/US2017/017501 US2017017501W WO2017139664A8 WO 2017139664 A8 WO2017139664 A8 WO 2017139664A8 US 2017017501 W US2017017501 W US 2017017501W WO 2017139664 A8 WO2017139664 A8 WO 2017139664A8
Authority
WO
WIPO (PCT)
Prior art keywords
synthesis
eribulin
intermediates
related methods
methods
Prior art date
Application number
PCT/US2017/017501
Other languages
French (fr)
Other versions
WO2017139664A1 (en
Inventor
Phil S. Baran
Charles E. Chase
Francis G. Fang
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2018009794A priority Critical patent/MX377663B/en
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Priority to EP17750887.6A priority patent/EP3413887B1/en
Priority to US16/076,028 priority patent/US10676481B2/en
Priority to CN201780010903.XA priority patent/CN108601760A/en
Priority to KR1020187025945A priority patent/KR20180107243A/en
Priority to RU2018132264A priority patent/RU2732575C2/en
Priority to JP2018539136A priority patent/JP6786610B2/en
Priority to SG11201806133UA priority patent/SG11201806133UA/en
Publication of WO2017139664A1 publication Critical patent/WO2017139664A1/en
Priority to IL260717A priority patent/IL260717B/en
Publication of WO2017139664A8 publication Critical patent/WO2017139664A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Photolithography (AREA)

Abstract

The invention relates to methods and intermediates useful in the synthesis of eribulin.
PCT/US2017/017501 2016-02-12 2017-02-10 Intermediates in the synthesis of eribulin and related methods of synthesis Ceased WO2017139664A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SG11201806133UA SG11201806133UA (en) 2016-02-12 2017-02-10 Intermediates in the synthesis of eribulin and related methods of synthesis
EP17750887.6A EP3413887B1 (en) 2016-02-12 2017-02-10 Intermediates in the synthesis of eribulin and related methods of synthesis
US16/076,028 US10676481B2 (en) 2016-02-12 2017-02-10 Intermediates in the synthesis of eribulin and related methods of synthesis
CN201780010903.XA CN108601760A (en) 2016-02-12 2017-02-10 Intermediates and related synthetic methods in the synthesis of Eribulin
KR1020187025945A KR20180107243A (en) 2016-02-12 2017-02-10 Intermediates and related synthetic methods in the synthesis of eribulin
MX2018009794A MX377663B (en) 2016-02-12 2017-02-10 INTERMEDIARIES IN THE SYNTHESIS OF ERIBULIN AND RELATED SYNTHESIS METHODS.
JP2018539136A JP6786610B2 (en) 2016-02-12 2017-02-10 Intermediates and related synthetic methods in the synthesis of eribulin
RU2018132264A RU2732575C2 (en) 2016-02-12 2017-02-10 Intermediate products in synthesis of eribulin and corresponding methods of synthesis
IL260717A IL260717B (en) 2016-02-12 2018-07-22 Intermediates in the synthesis of eribulin and related synthetic methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294538P 2016-02-12 2016-02-12
US62/294,538 2016-02-12

Publications (2)

Publication Number Publication Date
WO2017139664A1 WO2017139664A1 (en) 2017-08-17
WO2017139664A8 true WO2017139664A8 (en) 2018-07-26

Family

ID=59563582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/017501 Ceased WO2017139664A1 (en) 2016-02-12 2017-02-10 Intermediates in the synthesis of eribulin and related methods of synthesis

Country Status (10)

Country Link
US (1) US10676481B2 (en)
EP (1) EP3413887B1 (en)
JP (1) JP6786610B2 (en)
KR (1) KR20180107243A (en)
CN (1) CN108601760A (en)
IL (1) IL260717B (en)
MX (1) MX377663B (en)
RU (1) RU2732575C2 (en)
SG (1) SG11201806133UA (en)
WO (1) WO2017139664A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2748200T3 (en) 2004-06-03 2020-03-13 Eisai R&D Man Co Ltd Intermediates for the preparation of Halondondrin B
CN101883763B (en) 2007-10-03 2016-04-20 卫材R&D管理有限公司 Intermediates and methods for the synthesis of halichondrin B analogs
MX2012008510A (en) 2010-01-26 2012-11-21 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs.
RU2710545C2 (en) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Macrocyclization reactions and intermediate compounds and other fragments suitable for preparing analogues of halichondrin b
MX376869B (en) 2013-12-06 2025-03-07 Eisai R&D Man Co Ltd USEFUL METHODS IN THE SYNTHESIS OF HALICHONDRIN B ANALOGUES.
CN117024469A (en) 2015-05-07 2023-11-10 卫材R&D管理有限公司 Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments
JP7068204B2 (en) 2016-06-30 2022-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Prince reactions and intermediates useful for the synthesis of halichondrin macrolides and their analogs
SG11202005548WA (en) 2018-01-03 2020-07-29 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
CN110568121A (en) * 2019-07-11 2019-12-13 山东省药学科学院 A method for detecting related substances in eribulin and eribulin-containing preparations
KR102377262B1 (en) * 2020-05-11 2022-03-22 연성정밀화학(주) Crystalline Eribulin Salt

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (en) 1975-12-16 1979-03-15 Краснодарский политехнический институт Method of obtaining 1-(furyl-2')-2-(2-"formyl-furyl-5") ethylene and its methyl derivative as intermediate product for synthesis of furan-2,5-dicarboxylic acid
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (en) 1992-09-09 1995-09-01 Hoechst Ag
WO1998009942A1 (en) 1996-09-06 1998-03-12 Eli Lilly And Company Catalytic selective sulfonylation process
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
IL139960A0 (en) 1998-06-17 2002-02-10 Eisai Co Ltd Macrocylic analogs and methods of their use and preparation
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10106647A1 (en) 2001-02-12 2002-08-22 Univ Hannover Ratjadon derivatives to inhibit cell growth
ES2748200T3 (en) 2004-06-03 2020-03-13 Eisai R&D Man Co Ltd Intermediates for the preparation of Halondondrin B
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
WO2006076100A2 (en) 2004-12-09 2006-07-20 Eisai Co. Ltd. Tubulin isotype screening in cancer therapy using halichondrin b analogs
JP2009510005A (en) 2005-09-26 2009-03-12 シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト Intramolecular Prince reaction and catalyst suitable for the reaction
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
US8119839B2 (en) 2007-07-20 2012-02-21 Yamada Apiculture Center, Inc. Carboxylic acid and antidepressant composition containing the same as active ingredient
CN101883763B (en) 2007-10-03 2016-04-20 卫材R&D管理有限公司 Intermediates and methods for the synthesis of halichondrin B analogs
WO2009064029A1 (en) 2007-11-16 2009-05-22 Eisai R & D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
RU2517167C2 (en) 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Halichondrin b analogues
JP5371091B2 (en) 2009-01-23 2013-12-18 三菱レイヨン株式会社 Method for producing monosulfonic acid ester
MX2012008510A (en) 2010-01-26 2012-11-21 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs.
WO2012147900A1 (en) * 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
CA2857385A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
EP2831082B1 (en) 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
CA2916537C (en) 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
RU2710545C2 (en) 2013-11-04 2019-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Macrocyclization reactions and intermediate compounds and other fragments suitable for preparing analogues of halichondrin b
MX376869B (en) 2013-12-06 2025-03-07 Eisai R&D Man Co Ltd USEFUL METHODS IN THE SYNTHESIS OF HALICHONDRIN B ANALOGUES.
WO2016038624A1 (en) 2014-09-09 2016-03-17 Cipla Limited "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
CN117024469A (en) 2015-05-07 2023-11-10 卫材R&D管理有限公司 Macrocyclization reactions useful for the synthesis of halichondrin macrolides, intermediates and other fragments
JP7068204B2 (en) 2016-06-30 2022-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Prince reactions and intermediates useful for the synthesis of halichondrin macrolides and their analogs
WO2018217894A1 (en) 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
SG11202005548WA (en) 2018-01-03 2020-07-29 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof

Also Published As

Publication number Publication date
WO2017139664A1 (en) 2017-08-17
JP6786610B2 (en) 2020-11-18
CN108601760A (en) 2018-09-28
RU2018132264A (en) 2020-03-12
EP3413887A4 (en) 2019-08-14
SG11201806133UA (en) 2018-08-30
MX377663B (en) 2025-03-11
RU2732575C2 (en) 2020-09-21
US20190300542A1 (en) 2019-10-03
IL260717B (en) 2020-10-29
MX2018009794A (en) 2018-12-17
JP2019504839A (en) 2019-02-21
EP3413887B1 (en) 2021-04-07
RU2018132264A3 (en) 2020-04-15
EP3413887A1 (en) 2018-12-19
KR20180107243A (en) 2018-10-01
US10676481B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
WO2017139664A8 (en) Intermediates in the synthesis of eribulin and related methods of synthesis
WO2016134335A3 (en) Pvrig polypeptides and methods of treatment
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
WO2016149710A3 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2018081648A3 (en) Anti-mic antibidies and methods of use
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2015153513A8 (en) Anti-ox40 antibodies and methods of use
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
EP4361178A3 (en) Acid-alpha glucosidase variants and uses thereof
WO2014152157A8 (en) Methods and compositions for the generation and use of conformation-specific antibodies
WO2016100732A3 (en) Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
MY193650A (en) Extracellular matrix compositions
EP3325608A4 (en) Methods and microorganisms for the production of 1,3-butanediol
MX2019005855A (en) Powderous formulations.
WO2016020702A8 (en) Anti-tenascin c antibodies and uses thereof
WO2016079110A3 (en) Use of enzyme for cleaning
WO2016019036A3 (en) Recombinant collagen iv surrogates and uses thereof
WO2016138538A3 (en) Therapeutic use of integrin-binding antibodies
WO2016049185A3 (en) Synthetic rhinoceros horn analogues
IN2015CH01182A (en)
MX379715B (en) 7-SUBSTITUTED 1-ARYLNAPHTHYRIDINE-3-CARBOXAMIDES AND THEIR USE.
WO2015147834A8 (en) Bioactive glass and collagen combination products and kits
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17750887

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 260717

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2018539136

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11201806133U

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/009794

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187025945

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020187025945

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2017750887

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017750887

Country of ref document: EP

Effective date: 20180912